The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...

After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...

Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...

A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...

Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. | For the end of this year, ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...